Please assess the completion status of the following clinical trial:

Trial Title: LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged 18 years or older~* Must have received prior therapy for their WM, any number of prior therapies is allowed~* Must have symptomatic relapsed or refractory WM~* Measurable monoclonal IgM protein in the blood and presence of lymphoplasmacytic cells in the bone marrow during any previous bone marrow~* Laboratory values as described in the protocol~* Clinically euthyroid~* ECOG Performance Status of 2 or less~Exclusion Criteria:~* Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer~* Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment~* Peripheral neuropathy CTCAE grade 2 or higher~* Impaired cardiac function or clinically significant cardiac diseases~* Impairment of GI function or GI disease that may significantly alter the absorption of LBH589~* Diarrhea \> CTCAE grade 1~* Other concurrent severe and/or uncontrolled medical conditions including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol~* Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug~* Patients who have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies~* Patients who have received chemotherapy or rituximab within 3 weeks or less; or radiation therapy to \> 30% of marrow-bearing bone within 2 weeks or less prior to starting study treatment; or who have not yet recovered from side effects of such therapies~* Patients who have received corticosteroids 2 weeks or less prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than than Waldenstrom's Macroglobulinemia~* Patients with active bleeding tendency or receiving any treatment with therapeutic doses of sodium warfarin or coumadin derivatives. Low doses of Coumadin to maintain line patency is allowed~* Patients who have undergone major surgery 4 weeks or less prior to starting study drug or who have not recovered from side effects of such therapy~* Women who are pregnant or breast feeding or women of childbearing potential not using an effective method of birth control~* Male patients whose sexual partners are women of childbearing potential not using effective methods of birth control~* Patients with prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)~* Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required~* Patients with a significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LBH589 (Type: EXPERIMENTAL): 30 mg three days a week (Mondays, Wednesdays and Fridays).~1 cycle was 28 days~Dose modifications for attributable toxicities allowed for reduction to:~* 25 mg, 20 mg three times a week every week~* Or 20 mg three times a week every other week. No dose re-escalation was allowed.~  * The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).